Metabolic abnormalities and overweight in HIV/AIDS persons-treated with antiretroviral therapy

Revista de Nutricao

Volumn 21, Issue 3, 2008, Pages 277-283

  Leite, Luísa Helena Maia ^a   Sampaio, Ana Beatriz De Mattos Marinho ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Dyslipidemia; HIV; Insulin resistance; Obesity; Overweight

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 48849106791     PISSN: 14155273     EISSN: None     Source Type: Journal    
DOI: 10.1590/S1415-52732008000300002     Document Type: Article

References (21)

1. Brasil. Ministério da Saúde. Secretaria de Vigilância em Saúde. Programa Nacional de DST e Aids. Bol Epidemiol Aids e DST. 2006; 3(1)3-4.
2. Egir E, Vaichulonis CG, Oliveira MD. Adesão à terapêutica anti-retroviral por indivíduos com HIV/AIDS assistidos em uma instituição do interior paulista. Rev Latino-Am Enfermagem. 2005; 13(5):634-41.
3. Portela MC, Lotrowska M. Assistência aos pacientes com HIV/AIDS no Brasil. Rev Saúde Pública. 2006; 40(Supl 1):70-9.
4. Brasil. Ministério da Saúde. Secretaria de Vigilância em Saúde. Programa Nacional de DST e Aids. Recomendações para a terapia anti-retroviral em adultos e adolescentes infectados pelo HIV. 6 ed. Brasília; 2006. Série Normas e Manuais Técnicos.
5. Barbaro G. Reviewing the cardiovascular complications of HIV infection after the introduction of highly active antiretroviral therapy. Curr Drugs Targests Cardiovasc Haematol Disord. 2005; 5(4):337-43.
6. Yu PC, Calderaro D, Lima EMO, Caramelli B. Terapia hipolipemiante em situações especiais: síndrome da imunodeficiência adquirida. Arq Bras Cardiol 2005; 85(Suppl 5):58-61.
7. The data collection on adverse events of anti-HIV drugs (DAD) study group. Combination antiretroviral therapy and the risk of myocardial infarction. New Eng J Med. 2003; 349(21):1993-2003.
8. Savès M, Chêne G, Ducimetiere P, Leport C, Le Moal G, Amouyel P, et al. Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population. Clin Infect Dis. 2003; 37(2):292-8.
9. Thiébaut R, Savès M, Mercié P, Cipriano C, Chêne G, Dabis F. Épidémiologie du risque vasculaire d'origine athéroscléreuse chez les patients infectés par le VIH-1. Presse Med. 2003, 32(30):1419-26.
10. Jacobson DL, Tang AM, Spiegelman D, Thomas AM, Skinner S, Gorbach SL, et al. Incidence of metabolic syndrome in a cohort of HIV-infected adults and prevalence relative to the US population (National Health and Nutrition Examination Survey). J Acquir Immune Defic Syndr. 2006; 43(4):458-66.
11. Hendricks KM, Willis K, Houser R, Jones CY. Obesity in HIV-infection: dietary correlates. J Am Coll Nutr. 2006, 25(4):321-31.
12. Jaime PC, Florindo AA, Latorre MRDO, Brasil BG, Santos ECM, Segurado AAC. Prevalência de sobrepeso e obesidade abdominal em indivíduos portadores de HIV/AIDS, em uso de terapia anti-retroviral de alta potência. Rev Bras Epidemiol. 2004; 7(1):65-72.
13. Reaven GM. The insulin resistance syndrome: definition and dietary approaches to treatment. Ann Rev Nutr. 2005; 25(1):391-406.
14. Visnegarwala F, Raghavan SS, Mullin CM, Bartsch G, Wang J, Kotler D, et al. Sex differences in the association of HIV disease characteristics and body composition in antiretroviral naïve persons. Am J Clin Nutr. 2005; 82(4):850-6.
15. Chêne G. Risque cardiovasculaire et VIH. Impact des traitements antirétroviraux. La lettre de l'Infectiologue. 2004; 2(mars-avril):4-5.
16. Barbaro G, Klatt EC. Highly active antiretroviral therapy and cardiovascular complications in HIV-infected patients. Curr Pharm Des. 2003; 9(18):1475-8.
17. El-Sadr WM, Mullin CM, Carr A, Gilbert C, Rapport C, Visnegarwala F, et al. Effects of HIV disease on lipid, glucose and insulin levels: results from a large antiretroviral naïve cohort. HIV Med. 2005; 6(2):114-21.
18. Delarue J, Allain G, Guillerm S. Le syndrome métabolique. Nutr Clin Met. 2006; 20(2):114-7.
19. Shikuma CM, Day LJ, Gerschenson M. Insulin resistance in the HIV-infected population:the potential role of mitochondrial dysfunction. Curr Drug Targets Infect Disor. 2005; 5(3):255-62.
20. Fitch KV, Anderson EJ, Hubbard JL, Carpenter SJ, Waddell WR, Caliendo AM, et al. Effects of a lifestyle modification program in HIV-infected patients with metabolic syndrome. AIDS. 2006; 20(4):1843-50.
21. Davidson MH. Management of dyslipidemia in patients with complicated metabolic syndrome. A J Cardiol. 2005; 96(4A):22E-5E.